The undisclosed investment will grow Powdersize’s business while simultaneously adding a complete set of particle size control solutions to Xcelience’s portfolio. Powdersize will also continue to expand its recently added facility to support the additional business expected with the integration and shared development projects.
“As we continue to build our suite of services, we are excited to join with Powdersize in an integration that combines their leadership and 23 years of milling and micronizing experience, with our two decades of expertise in drug development,” said Derek Hennecke, President and CEO of Xcelience.
Solubility has become a hot topic for pharma companies, especially as many drugs in current companies’ pipelines are poorly soluble. Reducing particle size through micronization is considered the leading technology for increasing the bioavailability of oral dosage forms when the API has solubility issues.
“This collaboration is a natural fit for both sides,” says Wayne Sigler, CEO of Powdersize. “We fully expect both companies to benefit from each other’s strengths and capabilities in drug development and commercial products.”
Investment bank Fairmount Partners provided financial advisory services supporting the owners of Powdersize.